Manufacturing Plant in Oman for Anti-Cancer Medicine

A Pharma Group Company in Oman is in the process of setting up a manufacturing plant for Anti-Cancer medicine for the Global Market. The cost of the project is US$ 14 Million (OMR 5.4 Million) with a Project IRR of 31.6% and Payback Period of 5-6 years. Investors are invited for Equity Participation. Stake available up to 50%. 

GCCA conducted market analysis, feasibility study, and financial modeling for the project. We are also looking after the investor coordination and sourcing of investors for the project.